Executive Officer, Chief Financial Officer, Internal Auditor and our Chief Technical Officer. The aggregate of such cash compensation for the years ended December 31, 2020, 2021 and 2022 were $1.0 million, $1.0 million and $0.9 million, respectively.
Our executive officers and directors are also eligible to receive awards under our equity compensation plan described below under “— Equity Compensation Plan.” We did not grant any awards under our equity compensation plan to directors or officers of the Company during the years ended December 31, 2020 and 2022. In 2021, we granted restricted shares and stock options, including to our officers and directors, and in 2023 we granted restricted shares and stock options to our chief executive officer and restricted shares to our independent directors, each as described below under “— Equity Compensation Plan.” We recognized share-based compensation expense of nil, $0.6 million and $0.6 million in 2020, 2021 and 2022, respectively.
The Chairman of our Board of Directors receives annual fees of $70,000, plus reimbursement for his out-of-pocket expenses, while our other independent directors receive fees of $60,000 per annum in the aggregate, plus reimbursement of their out-of-pocket expenses. Executive directors receive no compensation for their services as directors.
Equity Awards
The Company’s directors and officers and employees of the management company are also eligible to receive compensation directly from the Company in the form of stock options, stock grants or other equity awards. Our equity compensation plan allows the plan administrator to grant awards of shares of our common stock or the right to receive or purchase shares of our common stock (including restricted stock, stock options and other awards) to our employees, directors or other persons providing significant services to us, including employees of our managers, or our subsidiaries. The aggregate number of shares of our common stock for which awards may be granted under our equity compensation plan cannot exceed 10% of the number of shares of our common stock issued and outstanding at the time any award is granted.
In August 2018, we awarded an aggregate of 264,621 restricted shares of common stock to directors and officers, all which vested in August 2021. We did not grant any awards under our equity compensation plan to directors or officers of the Company during the years ended December 31, 2019, 2020 and 2022. On May 26, 2021, 250,000 restricted shares of Common Stock and 250,000 shares of Common Stock subject to options with an exercise price of $2.99 per share and an option expiration date of May 25, 2031, which were granted to Mr. Vafias by the Company as compensatory awards, and an additional 93,744 restricted shares of Common Stock were granted, including an aggregate of 25,000 to our independent directors, to other recipients, which shares subsequently vested. In February 2023, we awarded (1) 250,000 restricted shares of common stock to our Chief Executive Officer with a vesting date of February 21, 2024 for 125,000 such shares and February 21, 2025 for 125,000 such shares, and (2) options exercisable to acquire 250,000 shares of the Company’s Common Stock at an exercise price per share equal to $2.85, the closing price of our common stock on February 21, 2023 and an option expiration date of February 21, 2033, with a vesting date of February 21, 2024 for 125,000 such option shares and February 21, 2025 for 125,000 such option shares. In February 2023, we also granted an aggregate of 27,000 restricted shares of common stock to our independent directors and an aggregate of 7,000 restricted shares of common stock to employees and service providers, 50% of which are scheduled to vest in February 2024 and 50% in February 2025. In May 2023, we granted 449,000 restricted shares to our Chief Executive Officer, with a vesting date of November 24, 2023. No equity awards were made for the years ended December 31, 2022 and 2020. As of July 31, 2023, awards with respect to an aggregate of 1,841,365 shares of our common stock had been granted under the 2015 Plan and awards with respect to 555,479 shares of our common stock were granted under our 2007 Plan from its adoption in 2005 to its expiration in August 2015. No additional awards can be granted under our 2007 Plan.
We recognized share-based compensation expense of nil, $0.6 million and $0.6 million in 2020, 2021 and 2022, respectively.
11